CAT overturns CMA’s excessive pricing decision against Pfizer and Flynn

On 7 December 2016, the Competition and Markets Authority (CMA) issued a decision entitled “Unfair pricing in respect of the supply of phenytoin sodium capsules in the UK” (the Decision) addressed to Pfizer Limited and Pfizer Inc. (toget...